Labcorp Holdings Inc. (LH)

In the past six months, Labcorp's stock has experienced several notable events. As of June 26, 2025, LH was up 3.75% over the past 30 days and 26.44% over the past 12 months. Redburn Atlantic initiated coverage with a "Buy" recommendation on April 2, 2025, and Citigroup upgraded its outlook for LH from "Neutral" to "Buy" on March 4, 2025. Labcorp reported its Q1 2025 earnings on April 29, 2025, with revenue increasing by 5.3% year-over-year to $3.3 billion. Labcorp announced strong Q4 2024 results on February 6, 2025, with revenue of $3.33 billion. The company has continued its acquisition strategy and declared a quarterly dividend of $0.72 per share, which was paid on June 11, 2025.

Demand for COVID-19 molecular tests is anticipated to fall to non-material levels in 2025, similar to that of seasonal flu. Assumptions for diagnostics growth have been "inched up" due to robust healthcare utilization. General or macroeconomic factors, including significant fluctuations in the economy, inflation, and increased costs of goods and services, could negatively impact testing volumes and drug development services. Revenues in the Drug Development segment depend on the pharmaceutical, biotechnology, and medical device industries, including their R&D spending and ability to raise capital.

Labcorp Holdings, Inc. is a leading global life sciences company based in the United States, primarily focused on providing comprehensive clinical laboratory and end-to-end drug development services. Labcorp operates through two main segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment offers a wide array of tests and focuses on four primary specialty testing areas: oncology, women's health, autoimmune disease, and neurology. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services, supporting pharmaceutical, biotechnology, and medical device companies. Labcorp also offers online and mobile applications for patients and providers.

Labcorp serves clients in approximately 100 countries and is headquartered in Burlington, North Carolina. In China, Labcorp opened a new kit production facility and expanded its immunology and immunotoxicology lab in July 2023. In Japan, Labcorp strengthened its central laboratory presence and drug development capabilities by expanding the CB Trial Laboratory in July 2022. In the United States, Labcorp has expanded into rural markets through deals like the acquisition of select operating assets of Ballad Health's outreach lab services and has completed acquisitions of assets and molecular testing locations in places like Birmingham, Alabama, and announced collaborations with health systems such as Inspira Health in New Jersey to manage hospital laboratories.

Information specifically detailing Labcorp's brand reputation in the past year is limited in the provided search results. However, general information indicates that Labcorp aims to enhance its reputation and reliability among healthcare professionals and patients through its strategic focus on innovation and customer service. Historically, Labcorp has received recognition, such as being named to FORTUNE magazine's "World's Most Admired Companies" list in 2018. No specific negative events impacting Labcorp's reputation in the past year were found in the provided search results.

Labcorp Holdings Inc. has a significant institutional ownership, with 1,713 institutional owners and shareholders holding a total of 91,313,805 shares as of recent filings. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. As of March 30, 2025, Vanguard Group, Inc. held 11.62% of shares, and BlackRock, Inc. held 11.08%. Institutional ownership accounts for 94.06% of the company.